Guidelines for Clinical Implementation of LATTICE Radiotherapy for the Treatment of Unresectable Bulky Uterine Cervical Cancer



Abstract

Objectives:

To establish a standardized protocol for Lattice Radiotherapy (LRT) for bulky loco-regionally advanced uterine cervical cancer. The proposed guidelines will include: adequate patient selection, detailed simulation and treatment planning recommendation, and strict dosimetric parameters to be reported in order to compare data.

Methods:

The LRT protocol is based on our experience of more than a decade of using LRT for voluminous cervical cancer and in the previously published International Consensus on the Design of prospective SFRT clinical trials for advanced gynecological cancer.

Results:

Patients with a tumor size of at least 4 cm will be included. Simulation will follow radiosurgery guidelines.
The course of treatment will be delivered in three phases:
Phase 1: LRT Boost
Five fractions of 8 Gy to the vertices, 2 Gy to the periphery of tumor, and valley dose under 5 Gy.

Phase 2: Pelvic RT
Dose of 45 Gy in 1.8 Gy per fraction with integrated boost to the PET+ lymph nodes.

Phase 3: Residual disease
Additional radiation or surgery.

Treatment time should not exceed 49 days with adaptive RT when needed.
Contouring, planning, and treatment delivery procedures will be outlined.

Conclusion(s):

Our preliminary results of using three LRT fractions of LRT combined with chemo-radiation for patients with bulky cervical cancer have demonstrated a complete tumor response of 70% with no grade 3 or 4 toxicity reported. The current protocol proposes a dose escalation using five LRT fractions as an upfront boost. The results regarding tumor control probability using this regimen are expected to be of at least 85%. Implementation of the standardized LRT protocol may lead to response rates evaluation between different institutions.

Related content

abstract
non-peer-reviewed

Guidelines for Clinical Implementation of LATTICE Radiotherapy for the Treatment of Unresectable Bulky Uterine Cervical Cancer


Author Information

Beatriz Amendola Corresponding Author

Radiation Oncology, Innovative Cancer Institute, South Miami, USA

Naipy C. Perez

Medical Physics, Innovative Cancer Institute, South Miami, USA

Michael Hall

Radiation Oncology, Innovative Cancer Institute, South Miami, USA

Marco A. Amendola

Radiation Oncology, Innovative Cancer Institute, South Miami, USA

Xiaodong Wu

Radiation Oncology, Innovative Cancer Institute, Cyberknife Center of Miami, South Miami, USA


PDF Share